Trial Profile
Non-resectable colorectal liver metastases treated with cetuximab induction toward liver R0 resection trial
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 19 May 2021
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Adenocarcinoma; Colorectal cancer; Liver metastases
- Focus Therapeutic Use
- Acronyms NEXTO
- 09 Dec 2016 Status changed from recruiting to active, no longer recruiting.
- 11 Oct 2016 Results (n=50) assessing efficacy and safety presented at the 41st European Society for Medical Oncology Congress.
- 16 May 2012 New trial record